Reserpine for the Treatment of Cocaine Dependence – 1


The purpose of this study is to assess the efficacy and safety of reserpine for the treatment of cocaine dependence.

Full Title of Study: “Phase 2, Double-Blind, Placebo-Controlled Trial of Reserpine for the Treatment of Cocaine Dependence”

Study Type

  • Study Type: Interventional
  • Study Design
    • Allocation: Randomized
    • Intervention Model: Parallel Assignment
    • Primary Purpose: Treatment
    • Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Detailed Description

To assess the efficacy and safety of reserpine in reducing cocaine use in subjects with cocaine dependence. This is a double-blind, placebo-controlled, parallel-group design with a 2 week baseline period.


  • Drug: Reserpine

Clinical Trial Outcome Measures

Primary Measures

  • Cocaine use
  • Addiction severity
  • Cocaine withdrawal
  • Adverse events
  • Clinical improvement

Participating in This Clinical Trial

Inclusion Criteria

Be at least 18 yrs of age; DSM-4 diagnosis of cocaine dependence; treatment seeking individuals; have the ability to understand and provide written informed consent; females of child bearing potential using appropriate birth control method Exclusion Criteria:

Additional criteria available during screening at the site.

Gender Eligibility: All

Minimum Age: 18 Years

Maximum Age: 99 Years

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • National Institute on Drug Abuse (NIDA)
  • Collaborator
    • Cincinnati VA Medical Center
  • Provider of Information About this Clinical Study
    • Liza Gorgon / Clinical Trials Specialist, NIDA
  • Overall Official(s)
    • Eugene Somoza, M.D., Ph.D., Principal Investigator, Cincinnati VA Medical Center

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.